A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women

Cancer Treatment Reviews

Volumn 39, Issue 5, 2013, Pages 457-465

  Cardoso, Fatima ^a   Bischoff, Joachim ^b   Brain, Etienne ^c   Zotano, Ángel Guerrero ^d   Lück, Hans Joachim ^e,i   Tjan Heijnen, Vivianne C ^f   Tanner, Minna ^g   Aapro, Matti ^h  

^a Champalimaud Cancer Center   (Portugal)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c INSTITUT CURIE   (France)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e Gynäkologisch Onkologische Praxis Hannover   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

^h CLINIQUE DE GENOLIER   (Switzerland)

ⁱ Univer sitätsfrauenklinikMagdeburg AöR ^*  (Germany)

Author keywords

Aromatase inhibitor; Breast cancer; Endocrine therapy; Fulvestrant; Metastatic; Postmenopausal; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ARTHRALGIA; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CROSS RESISTANCE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; TAMOXIFEN;

EID: 84876966562     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.06.011     Document Type: Review

References (78)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
2. Lu J., Steeg P.S., Price J.E., Krishnamurthy S., Mani S.A., Reuben J., et al. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009, 69:4951-4953.
3. Cardoso F., Senkus-Konefka E., Fallowfield L., Costa A., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v15-v19.
4. Moulder S., Hortobagyi G.N. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008, 83:26-36.
5. Rugo H.S. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008, 19:16-27.
6. Colleoni M., Gelber S., Coates A.S., Castiglione-Gertsch M., Gelber R.D., Price K., et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001, 19:4141-4149.
7. Astra Zeneca. ARIMIDEX (anastrozole) prescribing information; 2009.
8. Novartis Oncology. FEMARA (letrozole) prescribing information; 2010.
9. Pfizer I. AROMASIN (exemestane) prescribing information; 2008.
10. Buzdar A.U. Fulvestrant - a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc) 2008, 44:679-692.
11. Astra Zeneca. FASLODEX (fulvestrant) prescribing information; 2010.
12. Miller W.R. Aromatase inhibitors: prediction of response and nature of resistance. Expert Opin Pharmacother 2010, 11:1873-1887.
13. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995, 13:513-529.
14. Espie M. Megestrol acetate in advanced breast carcinoma. Oncology 1994, 51(Suppl. 1):8-12.
15. Abrams J., Aisner J., Cirrincione C., Berry D.A., Muss H.B., Cooper M.R., et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol 1999, 17:64-73.
16. Buzdar A., Douma J., Davidson N., Elledge R., Morgan M., Smith R., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001, 19:3357-3366.
17. Buzdar A.U., Jonat W., Howell A., Jones S.E., Blomqvist C.P., Vogel C.L., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
18. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000, 18:1399-1411.
19. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18:3748-3757.
20. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
21. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109.
22. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
23. Chernozemsky I, Kalinov K, Tzekov H, Racheva M, Hristova S, Tomova A, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer. In: Poster presentation at San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA; 2007.
24. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
25. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
26. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thurlimann B., Paridaens R., Smith I., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776.
27. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
28. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
29. Chan A, Speers C, O'Reilly S, Pickering R, Chia S. Adherence of adjuvant hormonal therapies in postmenopausal hormone receptor-positive (HR+) early stage breast cancer: a population based study from British Columbia. In: Oral presentation at San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA; 2009.
30. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010, 73:156-166.
31. Hackshaw A., Roughton M., Forsyth S., Monson K., Reczko K., Sainsbury R., et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011, 29:1657-1663.
32. Miller W.R., Bartlett J., Brodie A.M., Brueggemeier R.W., Di S.E., Lonning P.E., et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837.
33. Hong Y., Yu B., Sherman M., Yuan Y.C., Zhou D., Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 2007, 21:401-414.
34. Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000, 18:2234-2244.
35. Bertelli G., Garrone O., Merlano M., Occelli M., Bertolotti L., Castiglione F., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69:471-477.
36. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670.
37. Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
38. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386-3395.
39. Robertson J.F. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007, 12:774-784.
40. Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E., et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009, 27:4530-4535.
41. Pritchard K.I., Rolski J., Papai Z., Mauriac L., Cardoso F., Chang J., et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010, 123:453-461.
42. Di Leo A., Bondarenko I.N., Khasanov R., et al. Results of the CONFIRM Phase III Trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
43. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
44. Perez E.A. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007, 18(Suppl. 8):viii26-viii35.
45. Crivellari D., Spazzapan S., Puglisi F., Fratino L., Scalone S., Veronesi A. Hormone therapy in elderly breast cancer patients with comorbidities. Crit Rev Oncol Hematol 2010, 73:92-98.
46. Aapro M.S. Challenges in clinical patient management. Cancer Invest 2010, 28(Suppl. 1):14-27.
47. Hargis J.B., Nakajima S.T. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest 2006, 24:174-177.
48. Recommendations Gynakologische Onkologie Commission Mamma. Endokrine Therapie des metastasierten Mammakarzinoms. <>; 2010. http://www.ago-online.de.
49. Lonning P.E. Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncol 2009, 48:1092-1101.
50. Kyritsis V., de Lemos M., Speers C., Barnett J. Survival analysis of sequential use of first-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women. J Clin Oncol 2008, 26. (abstr. 1093).
51. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
52. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
53. Barone I., Brusco L., Fuqua S.A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010, 16:2702-2708.
54. Miyoshi Y., Murase K., Saito M., Oh K. Prediction of hormone sensitivity for breast cancers. Breast cancer 2010, 17:86-91.
55. Ingle J.N. Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res 2008, 10(Suppl. 4):S17.
56. Macedo L.F., Sabnis G.J., Goloubeva O.G., Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 2008, 68:3516-3522.
57. Bergh J, Jonsson P, Lidbrink E, Trudeau M, Eiermann W, Brattstrom D, et al. First results from FACT - an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. In: Oral presentation at San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA; 2009.
58. Mehta R, Barlow W, Albain K, Vandenberg T, Dakhil S, Tirumali N, et al. A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. In: Oral presentation at San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA; 2011.
59. Thurlimann B., Paridaens R., Serin D., Bonneterre J., Roche H., Murray R., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997, 33:1767-1773.
60. Lonning P.E., Taylor P.D., Anker G., Iddon J., Wie L., Jorgensen L.M., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001, 67:111-116.
61. Nicholson R.I., Hutcheson I.R., Jones H.E., Hiscox S.E., Giles M., Taylor K.M., et al. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 2007, 8:241-253.
62. Arpino G., Gutierrez C., Weiss H., Rimawi M., Massarweh S., Bharwani L., et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007, 99:694-705.
63. Johnston S.R., Semiglazov V.F., Manikhas G.M., Spaeth D., Romieu G., Dodwell D.J., et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008, 110:327-335.
64. Chow L., Sun Y., Jassem J. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl. 1):S286. (abstr. 6091).
65. Cristofanilli M., Valero V., Mangalik A., Royce M., Rabinowitz I., Arena F.P., et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16:1904-1914.
66. Osborne C.K., Neven P., Dirix L.Y., Mackey J.R., Robert J., Underhill C., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17:1147-1159.
67. Beeram M., Tan Q.T., Tekmal R.R., Russell D., Middleton A., DeGraffenried L.A. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18:1323-1328.
68. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011.
69. Bachelot T, Bourgier C, Cropet C, Guastalla JP, Ferrero J, Leger-Falandry C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients with hormone receptor-positive HER2-negative metastatic breast cancer with prior exposure to aromatase inhibitors. In: Oral presentation at San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA; 2010 (abstr. S1-6).
70. Bhattacharyya G, Biswas J, Singh J, Singh M, Govindbabu K, Ranade A, et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. In: European Multidisciplinary Cancer Congress; 2011 (late breaking abstract 16).
71. Dafni U., Grimani I., Xyrafas A., Eleftheraki A.G., Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010, 119:621-631.
72. Pal SK, Gupta R, Bernstein L, Mortimer JE. Lack of survival benefit in metastatic breast cancer with newer chemotherapy agents: The City of Hope cancer experience. In: Poster presentation at American Society of Clinical Oncology Breast Cancer Symposium; 2008 (abstr. 95).
73. Mayer M. Lessons learned from the metastatic breast cancer community. Semin Oncol Nurs 2010, 26:195-202.
74. Cardoso F. Metastatic breast cancer patients: the forgotten heroes!. Breast 2009, 18:271-272.
75. Bridging gaps, expanding outreach: Metastatic Breast Cancer Advocacy Working Group Consensus Report. January 25, 2008. Breast 2009;18:273-5.
76. Brodie A., Njar V., Macedo L.F., Vasaitis T.S., Sabnis G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol 2009, 27:53-63.
77. Palmieri C., Januszewski A., Stanway S., Coombes R.C. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther 2011, 11:179-183.
78. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.